Dimensional Fund Advisors
ADMA icon

Dimensional Fund Advisors’s ADMA Biologics ADMA Stock Holding History

Dimensional Fund Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.2M Sell
3,606,208
-1,399,273
-28% -$12.8M 0.01% 1848
2026
Q1 		$45.1M Buy
5,005,481
+169,843
+4% +$2.68M 0.01% 1554
2025
Q4 		$88.2M Buy
4,835,638
+37,364
+0.8% +$630K 0.02% 1165
2025
Q3 		$70.3M Buy
4,798,274
+35,199
+0.7% +$603K 0.02% 1315
2025
Q2 		$86.7M Sell
4,763,075
-97,239
-2% -$1.98M 0.02% 1124
2025
Q1 		$96.4M Buy
4,860,314
+191,994
+4% +$3.32M 0.02% 1005
2024
Q4 		$80.1M Buy
4,668,320
+643,661
+16% +$12.1M 0.02% 1214
2024
Q3 		$80.4M Buy
4,024,659
+866,699
+27% +$13.5M 0.02% 1198
2024
Q2 		$35.3M Sell
3,157,960
-440,076
-12% -$3.69M 0.01% 1677
2024
Q1 		$23.7M Buy
3,598,036
+106,975
+3% +$585K 0.01% 1896
2023
Q4 		$15.8M Buy
3,491,061
+561,243
+19% +$2.08M ﹤0.01% 2102
2023
Q3 		$10.5M Buy
2,929,818
+1,651,433
+129% +$6.36M ﹤0.01% 2222
2023
Q2 		$4.72M Buy
1,278,385
+1,222,854
+2,202% +$4.53M ﹤0.01% 2549
2023
Q1 		$184K Buy
+55,531
New +$192K ﹤0.01% 3220
2022
Q3 		$141K Sell
58,179
-5,783
-9% -$13.9K ﹤0.01% 3292
2022
Q2 		$126K Buy
63,962
+6,290
+11% +$12.4K ﹤0.01% 3299
2022
Q1 		$106K Hold
57,672
– – ﹤0.01% 3387
2021
Q4 		$81K Sell
57,672
-45,546
-44% -$59.9K ﹤0.01% 3454
2021
Q3 		$117K Sell
103,218
-36,095
-26% -$50.6K ﹤0.01% 3412
2021
Q2 		$223K Sell
139,313
-12,400
-8% -$21.8K ﹤0.01% 3320
2021
Q1 		$267K Buy
+151,713
New +$347K ﹤0.01% 3242
2020
Q4 		– Sell
-11,840
Closed -$28K – 3343
2020
Q3 		$28K Buy
+11,840
New +$32.5K ﹤0.01% 3319
2019
Q2 		– Sell
-14,127
Closed -$54K – 3464
2019
Q1 		$54K Hold
14,127
– – ﹤0.01% 3407
2018
Q4 		$34K Buy
+14,127
New +$70K ﹤0.01% 3412

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Dimensional Fund Advisors's ADMA Position: Q2 2026 in Review

Dimensional Fund Advisors reduced its ADMA Biologics (ADMA) stake by 28% in Q2 2026, selling an estimated $12.8M and leaving 3,606,208 shares worth $30.2M. The position accounts for 0.01% of the portfolio, ranked #1848.

Dimensional Fund Advisors first reported a position in ADMA in Q4 2018 and has held it in 24 quarters since. The position peaked at $96.4M in Q1 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Dimensional Fund Advisors held 3,606,208 shares of ADMA Biologics worth $30.2M as of Q2 2026.
  • Dimensional Fund Advisors sold 1,399,273 ADMA Biologics shares in Q2 2026, an estimated $12.8M.
  • ADMA Biologics made up 0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #1848 holding.
  • Dimensional Fund Advisors first reported a position in ADMA Biologics in Q4 2018 and has held it in 24 quarters since.
  • Dimensional Fund Advisors's ADMA Biologics position peaked at $96.4M in Q1 2025.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.